210 related articles for article (PubMed ID: 35147166)
1. Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo.
Clerk A; Meijles DN; Hardyman MA; Fuller SJ; Chothani SP; Cull JJ; Cooper STE; Alharbi HO; Vanezis K; Felkin LE; Markou T; Leonard SJ; Shaw SW; Rackham OJL; Cook SA; Glennon PE; Sheppard MN; Sembrat JC; Rojas M; McTiernan CF; Barton PJ; Sugden PH
Biochem J; 2022 Feb; 479(3):401-424. PubMed ID: 35147166
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice.
Alharbi HO; Hardyman MA; Cull JJ; Markou T; Cooper STE; Glennon PE; Fuller SJ; Sugden PH; Clerk A
Clin Sci (Lond); 2022 Nov; 136(22):1661-1681. PubMed ID: 36331065
[TBL] [Abstract][Full Text] [Related]
3. Central role for BRAF in cardiac hypertrophy: rethinking the pathological-physiological divide.
Altara R; Booz GW
Clin Sci (Lond); 2023 Jan; 137(2):143-148. PubMed ID: 36651286
[TBL] [Abstract][Full Text] [Related]
4. The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension.
Meijles DN; Cull JJ; Cooper STE; Markou T; Hardyman MA; Fuller SJ; Alharbi HO; Haines ZHR; Alcantara-Alonso V; Glennon PE; Sheppard MN; Sugden PH; Clerk A
Clin Sci (Lond); 2021 Jul; 135(14):1631-1647. PubMed ID: 34296750
[TBL] [Abstract][Full Text] [Related]
5. Raf-mediated cardiac hypertrophy in adult Drosophila.
Yu L; Daniels J; Glaser AE; Wolf MJ
Dis Model Mech; 2013 Jul; 6(4):964-76. PubMed ID: 23580199
[TBL] [Abstract][Full Text] [Related]
6. Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation.
Tanner MA; Thomas TP; Grisanti LA
J Mol Cell Cardiol; 2019 Nov; 136():1-14. PubMed ID: 31473246
[TBL] [Abstract][Full Text] [Related]
7. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
8. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
9. B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy.
Kramann N; Hasenfuß G; Seidler T
Cardiovasc Res; 2014 Apr; 102(1):88-96. PubMed ID: 24492844
[TBL] [Abstract][Full Text] [Related]
10. KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy.
Wang Y; Liao H; Wang Y; Zhou J; Wang F; Xie Y; Zhao K; Gao W
BMC Cardiovasc Disord; 2021 May; 21(1):266. PubMed ID: 34059001
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
12. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
13. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy.
Oceandy D; Pickard A; Prehar S; Zi M; Mohamed TM; Stanley PJ; Baudoin-Stanley F; Nadif R; Tommasi S; Pfeifer GP; Armesilla AL; Cartwright EJ; Neyses L
Circulation; 2009 Aug; 120(7):607-16. PubMed ID: 19652091
[TBL] [Abstract][Full Text] [Related]
15. Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload.
Zhou H; Shen DF; Bian ZY; Zong J; Deng W; Zhang Y; Guo YY; Li H; Tang QZ
PLoS One; 2011; 6(10):e26744. PubMed ID: 22053207
[TBL] [Abstract][Full Text] [Related]
16. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
Cell Stress Chaperones; 2020 Nov; 25(6):899-908. PubMed ID: 32519137
[TBL] [Abstract][Full Text] [Related]
17. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
[TBL] [Abstract][Full Text] [Related]
18. Differential ERK1/2 Signaling and Hypertrophic Response to Endothelin-1 in Cardiomyocytes from SHR and Wistar-Kyoto Rats: A Potential Target for Combination Therapy of Hypertension.
Zhu LA; Fang NY; Gao PJ; Jin X; Wang HY; Liu Z
Curr Vasc Pharmacol; 2015; 13(4):467-74. PubMed ID: 25360842
[TBL] [Abstract][Full Text] [Related]
19. Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
Tamura S; Marunouchi T; Tanonaka K
J Mol Cell Cardiol; 2019 Feb; 127():134-142. PubMed ID: 30582930
[TBL] [Abstract][Full Text] [Related]
20. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway.
Cai J; Yi FF; Bian ZY; Shen DF; Yang L; Yan L; Tang QZ; Yang XC; Li H
J Cell Mol Med; 2009 May; 13(5):909-25. PubMed ID: 19413885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
